drugset / Trial / NCT04070755

Dermal Photo Allergic Skin Reaction

NCT04070755 ↗

Phase 1 Completed 56 enrolled Vyne Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

A 6-Week, Randomized Study to Evaluate the Potential of FMX-101, 4% And Vehicle to Induce a Photo Allergic Skin Reaction in Healthy Volunteers, Using a Controlled Photo Patch Test Design

Timeline

Start
2016-09-21
Primary completion
2016-11-18
Completion
2016-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject FMX-101 Unknown — —

Indications

No indication recorded.